Abstract 7P
Background
Clear cell renal cell carcinoma (ccRCC), accounting for 80% of renal cell carcinoma (RCC) cases, is a common and deadly urological cancer. Only a small proportion of ccRCC patients obtain durable benefits from immunotherapy. Therefore, exploring novel predictive biomarkers for immunotherapy would be beneficial in guiding personalized clinical management for ccRCC patients.
Methods
The mass spectrum (MS) analyzation, co-immunoprecipitation (Co-IP), immunocytochemistry (ICC) are conducted to identify and confirm the interaction of ACOX2 and MRE11. The protein markers are detected by western blot (WB) and ICC to evaluate the effects of ACOX2 on homologous recombination repair (HRR) and double-strand break (DSB). Picogreen dyeing, WB, ELISA, and immunohistochemistry (IHC) are applied to test the role of ACOX2 in cGAS-STING pathway. Multiple immunohistochemistry (mIHC) and multiple immunofluorescence (mIF) are conducted to assess the association of ACOX2 expression and tertiary lymphoid structures (TLS) maturity. IC50 and clone formation assay are carried out to detected the sensitivity of PARPi to ccRCC cells with different expression level of ACOX2. Patient-derived organoids (PDOs), patient-derived xenografts (PDXs), and immunocompetent mouse models are applied to investigate the predictive value of ACOX2 to the therapeutic effect of PARPi plus anti-PD-1 antibody combination therapy in ccRCC.
Results
ACOX2 interacts with MRE11 and inhibits the binding of MRE11 and RAD50, thereby disturbing the stability of MRE11-RAD50-NBS1 (MRN) complex. Over-expressed of ACOX2 inhibits the HRR efficiency and causes the accumulation of DSBs in ccRCC cells. Furthermore, ACOX2 activates the cGAS-STING pathway and induces the formation of more mature TLS, contributing to immune-activated tumor microenvironment in ccRCC. Therapeutically, ACOX2 augments the efficacy of PARPi plus anti-PD-1 antibody combination therapy in vivo.
Conclusions
Our findings reveal a key inhibiting role of ACOX2 in HRR and suggest that the combination therapy of PARPi plus ICI could be a promising treatment strategy for ccRCC patients with elevated ACOX2 expression.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
185P - Characterizing the metabolic reprogramming of mutant ß-catenin in hepatocellular carcinoma
Presenter: Nathalie Wong
Session: Poster Display session
Resources:
Abstract
186P - Unveil and overcome PD(L)1 antibody resistance via functional genomics and clinical derived biopsies
Presenter: BIN XIE
Session: Poster Display session
Resources:
Abstract
187P - Single-cell RNA sequencing elucidates the role of intercommunication between epithelial cells, immune cells, and fibroblasts in high-grade serous ovarian cancer
Presenter: Xiaoting Zhao
Session: Poster Display session
Resources:
Abstract
188P - Single-cell and spatial transcriptomics delineate the microstructure and immune landscape of intrahepatic cholangiocarcinoma in the leading-edge area
Presenter: Zuyin li
Session: Poster Display session
Resources:
Abstract
189P - Image-guided labeling of live cells in tertiary lymphoid structures for single-cell transcriptomics
Presenter: Mengrui Cao
Session: Poster Display session
Resources:
Abstract
190P - Ex vivo modeling of precision immuno-oncology responses in lung cancer
Presenter: Bassel Alsaed
Session: Poster Display session
Resources:
Abstract
191P - Patient-derived 3D-bioprinted tumours as a relevant and innovative tool for immunotherapeutic testing.
Presenter: Kamila Pawlicka
Session: Poster Display session
Resources:
Abstract
192P - A new neuroendocrine model and in vitro effect of melatonin and serotonin on the PD-L1 ligand and its immunomodulatory action
Presenter: Dulce Caraveo Gutiérrez
Session: Poster Display session
Resources:
Abstract
193P - Humanized mice applying CD47; Prkcd; IL2rg triple KO mice exhibit enhanced human immune cell engraftment and reduced GvHD symptoms
Presenter: Seung-Ho Heo
Session: Poster Display session
Resources:
Abstract
194P - The impact of BTK inhibitors on ?d T cell fitness: Lesson for immunotherapy
Presenter: Adam Michalski
Session: Poster Display session
Resources:
Abstract